Investigational agents for treatment of traumatic brain injury
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Traumatic brain injury (TBI) is a major cause of death and disability worldwide. To date, there are no pharmacologic agents proven to improve outcomes from TBI because all the Phase III clinical trials in TBI have failed. Thus, there is a compelling need to develop treatments for TBI. AREAS COVERED: The following article provides an overview of select cell-based and pharmacological therapies under early development for the treatment of TBI. These therapies seek to enhance cognitive and neurological functional recovery through neuroprotective and neurorestorative strategies. EXPERT OPINION: TBI elicits both complex degenerative and regenerative tissue responses in the brain. TBI can lead to cognitive, behavioral, and motor deficits. Although numerous promising neuroprotective treatment options have emerged from preclinical studies that mainly target the lesion, translation of preclinical effective neuroprotective drugs to clinical trials has proven challenging. Accumulating evidence indicates that the mammalian brain has a significant, albeit limited, capacity for both structural and functional plasticity, as well as regeneration essential for spontaneous functional recovery after injury. A new therapeutic approach is to stimulate neurovascular remodeling by enhancing angiogenesis, neurogenesis, oligodendrogenesis, and axonal sprouting, which in concert, may improve neurological functional recovery after TBI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-coding RNAs in human disease
Esteller, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3074 · Cited by 4,825 · cited 1×
“5 microRNAs miRNAs are small (~ 22 nucleotides) noncoding RNAs that regulate gene expression at the post-transcriptional level, either by translational repression or mRNA degradation [167].”
BackgroundThe impact of traumatic brain injuries: A global perspective
Hyder, A. A., Wunderlich, C. A., Puvanachandra, P., Gururaj, G., & Kobusingye, O. C. (2007) · Neurorehabilitation · doi:10.3233/nre-2007-22502 · Cited by 1,816 · cited 1×
“Globally, at least 10 million TBIs serious enough to result in death or hospitalization occur each year [3,4].”
BackgroundPosition statement: definition of traumatic brain injury
Menon, D. K., Schwab, K., Wright, D. W., & Maas, A. I. (2010) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2010.05.017 · Cited by 1,678
Cleavage of proBDNF by tPA/Plasmin Is Essential for Long-Term Hippocampal Plasticity
Pang, P. T., Teng, H. K., Zaitsev, E., Woo, N. T., Sakata, K., Zhen, S., Teng, K. K., Yung, W.-H., Hempstead, B. L., & Lu, B. (2004) · Science · doi:10.1126/science.1100135 · Cited by 1,136
Clinical trials in head injury
Narayan, R. K., Michel, M. E., Ansell, B., Baethmann, A., Biegon, A., Bracken, M. B., Bullock, M. R., Choi, S. C., Clifton, G. L., Contant, C. F., et al. (2002) · Journal of Neurotrauma · doi:10.1089/089771502753754037 · Cited by 913 · cited 3×
“Over the past 40 years, > 100 RCTs in TBI were conducted [11,23,34-41].”
BackgroundZhang, Y., Chopp, M., Meng, Y., Katakowski, M., Xin, H., Mahmood, A., & Xiong, Y. (2015) · Journal of neurosurgery · doi:10.3171/2014.11.jns14770 · Cited by 737
Self-citationLoane, D. J., & Faden, A. I. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.005 · Cited by 574 · cited 6×
“These failures likely reflect methodological differences between the clinical and animal studies, as well as inadequate preclinical evaluation and/or clinical trial designs (Table 3) [11,44,45].”
BackgroundInfluentialExosomes for drug delivery—A novel application for the mesenchymal stem cell
Lai, R. C., Yeo, R. W. Y., Tan, K. H., & Lim, S. K. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.008 · Cited by 546 · cited 1×
“The refinement of MSC therapy from a cellbased to cell-free exosome-based therapy offers several advantages, as it eases the arduous task of preserving cell viability and function, storage and delivery to patient because their bi-lipid membranes can protect their biologically active cargo allowing for easier storage o…”
BackgroundA Clinical Trial of Progesterone for Severe Traumatic Brain Injury
Skolnick, B. E., Maas, A. I., Narayan, R. K., van der Hoop, R. G., MacAllister, T., Ward, J. D., Nelson, N. R., & Stocchetti, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411090 · Cited by 505 · cited 6×
“Age Mainly young adult 16 -- 94 years old, mainly young [24,25,50,51] Sex Mainly males Mixed (male sex, 70 -- 80%) [24,25,50,51] Initial intervention time Most < 1 h Average 3.”
BackgroundInfluentialCernak, I. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.410 · Cited by 462
Clinical trials in traumatic brain injury: past experience and current developments
Maas, A. I. R., Roozenbeek, B., & Manley, G. T. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2009.10.022 · Cited by 291 · cited 1×
“Over the past 40 years, > 100 RCTs in TBI were conducted [11,23,34-41].”
BackgroundProtective astrogenesis from the SVZ niche after injury is controlled by Notch modulator Thbs4
Benner, E. J., Luciano, D., Jo, R., Abdi, K., Paez-Gonzalez, P., Sheng, H., Warner, D. S., Liu, C., Eroglu, C., & Kuo, C. T. (2013) · Nature · doi:10.1038/nature12069 · Cited by 282 · cited 1×
“Although reactive astrocytes form an inhibitory glial scar following TBI, astrocytes are involved in neuroprotection [177], axonal remodeling, and functional recovery in animal models of neural injury [178,179].”
BackgroundThymosin β: actin-sequestering protein moonlights to repair injured tissues
GOLDSTEIN, A., HANNAPPEL, E., & KLEINMAN, H. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.07.004 · Cited by 250
The Effect of Gender on Patients With Moderate to Severe Head Injuries
Berry, C., Ley, E. J., Tillou, A., Cryer, G., Margulies, D. R., & Salim, A. (2009) · Journal of Trauma: Injury, Infection & Critical Care · doi:10.1097/ta.0b013e3181ba3354 · Cited by 197 · cited 1×
“The difference seen in females after TBI has conflicting evidence [52].”
BackgroundmiR-21 improves the neurological outcome after traumatic brain injury in rats
Ge, X.-T., Lei, P., Wang, H.-C., Zhang, A.-L., Han, Z.-L., Chen, X., Li, S.-H., Jiang, R.-C., Kang, C.-S., & Zhang, J.-N. (2014) · Scientific Reports · doi:10.1038/srep06718 · Cited by 167 · cited 2×
“A recent study manipulated the expression level of miR-21 in brain using intracerebroventricular infusion of miR-21 agomir or antagomir to evaluate the potential effect of miR-21 on neurological function in the fluid percussion injury rat model of TBI [173].”
BackgroundMethodA review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury
McConeghy, K. W., Hatton, J., Hughes, L., & Cook, A. M. (2012) · CNS Drugs · doi:10.2165/11634020-000000000-00000 · Cited by 158 · cited 1×
“Over the past 40 years, > 100 RCTs in TBI were conducted [11,23,34-41].”
BackgroundWagner, A. K., Willard, L. A., Kline, A. E., Wenger, M. K., Bolinger, B. D., Ren, D., Zafonte, R. D., & Dixon, C. E. (2004) · Brain Research · doi:10.1016/j.brainres.2003.11.027 · Cited by 141
Exploring new routes for neuroprotective drug development in traumatic brain injury
Janowitz, T., & Menon, D. K. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000330 · Cited by 74 · cited 1×
“During the past three decades, > 30 clinical trials for potential treatment of TBI have been initiated, and almost all Phase II/III TBI clinical trials have failed [11,15]; consequently, no effective treatment options currently exist that improve the neurological outcome after TBI.”
BackgroundCyclosporin A disposition following acute traumatic brain injury
Empey, P. E., McNamara, P. J., Young, B., Rosbolt, M. B., & Hatton, J. (2006) · Journal of Neurotrauma · doi:10.1089/neu.2006.23.109 · Cited by 58 · cited 1×
“The good safety and tolerability profile of CsA was established in humans when it was administered early after severe TBI [73-75].”
BackgroundRuff, D., Crockford, D., Girardi, G., & Zhang, Y. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05474.x · Cited by 46 · cited 1×
“dose or in multiple daily doses for 14 days over a dose range of 42 -- 1260 mg was well tolerated with no evidence of dose limiting toxicity in healthy humans [145].”
BackgroundSelf-citationCombination therapies for traumatic brain injury: prospective considerations
Margulies, S. S., & Hicks, R. (2009) · Journal of Neurotrauma · doi:10.1089/neu.2008-0794 · Cited by 22
Cited by
Huang, S., Ge, X., Yu, J., Han, Z., Yin, Z., Li, Y., Chen, F., Wang, H., Zhang, J., & Lei, P. (2018) · The FASEB Journal · doi:10.1096/fj.201700673r · Cited by 388
Traumatic Brain Injury: Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets
Thapa, K., Khan, H., Singh, T. G., & Kaur, A. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01841-7 · Cited by 341
“The effects of rosuvastatin on TBI-stimulated cytokine variation were evaluated in a phase I/II trial (NCT00990028) (Xiong et al. 2015).”
MethodChen, J., & Chopp, M. (2018) · Stroke · doi:10.1161/strokeaha.117.018292 · Cited by 152
Self-citationSmall extracellular vesicles as potential theranostic tools in central nervous system disorders
Guo, M., Wang, L., Yin, Z., Chen, F., & Lei, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115407 · Cited by 4
Metadata
- Authors
- Xiong, Y., Zhang, Y., Mahmood, A., & Chopp, M.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2015-03
- Volume
- 24
- Issue
- 6
- Pages
- 743-760
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2002448470
- Cited by
- 91
- References
- 21
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.